SGI-110 in Combination With Carboplatin in Ovarian Cancer
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
A 2-part, Phase 2 controlled, open-label, randomized study in participants with
platinum-resistant recurrent ovarian cancer. In Part 1, participants received SGI-110 and
carboplatin. The optimum dose of SGI-110 (guadecitabine) was identified in Part 1 based on
safety and efficacy. In Part 2, participants were randomized to receive the dose identified
in Part 1 plus carboplatin or one of four treatment of choice at the discretion of the
investigator. The treatment of choice consisted of topotecan, pegylated liposomal
doxorubicin, paclitaxel or gemcitabine.